APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripherally Acting Anti-Obesity Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peripherally Acting Anti-Obesity Drug Market Outlook and Growth Opportunities 2026

21 December 2025198 pages

Choose your research edition.

Industry ResearchPeripherally Acting Anti-Obesity Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripherally Acting Anti-Obesity Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peripherally Acting Anti-Obesity Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripherally Acting Anti-Obesity Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripherally Acting Anti-Obesity Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peripherally Acting Anti-Obesity Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peripherally Acting Anti-Obesity Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peripherally Acting Anti-Obesity Drug market include Novo Nordisk A/S, Pfizer Inc., GlaxoSmithKline plc, Vivus LLC., Rhythm Pharmaceuticals, KVK Tech Inc., Gelesis Holdings, Currax Pharmaceuticals LLC and CHEPLAPHARM Arzneimittel GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peripherally Acting Anti-Obesity Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peripherally Acting Anti-Obesity Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peripherally Acting Anti-Obesity Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peripherally Acting Anti-Obesity Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Peripherally Acting Anti-Obesity Drug Segment by Company

Novo Nordisk A/S

Pfizer Inc.

GlaxoSmithKline plc

Vivus LLC.

Rhythm Pharmaceuticals

KVK Tech Inc.

Gelesis Holdings

Currax Pharmaceuticals LLC

CHEPLAPHARM Arzneimittel GmbH

Boehringer Ingelheim International GmbH

Peripherally Acting Anti-Obesity Drug Segment by Type

Prescription Drugs

Non-prescription Drugs

Peripherally Acting Anti-Obesity Drug Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Peripherally Acting Anti-Obesity Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peripherally Acting Anti-Obesity Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peripherally Acting Anti-Obesity Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peripherally Acting Anti-Obesity Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Peripherally Acting Anti-Obesity Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripherally Acting Anti-Obesity Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripherally Acting Anti-Obesity Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripherally Acting Anti-Obesity Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peripherally Acting Anti-Obesity Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peripherally Acting Anti-Obesity Drug industry.

Chapter 3: Detailed analysis of Peripherally Acting Anti-Obesity Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peripherally Acting Anti-Obesity Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peripherally Acting Anti-Obesity Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peripherally Acting Anti-Obesity Drug Industry Trends Table 2. Peripherally Acting Anti-Obesity Drug Industry Drivers Table 3. Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges Table 4. Peripherally Acting Anti-Obesity Drug Industry Restraints Table 5. Global Peripherally Acting Anti-Obesity Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peripherally Acting Anti-Obesity Drug Revenue Share by Company (2021-2026) Table 7. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Company (2021-2026) Table 9. Global Peripherally Acting Anti-Obesity Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Peripherally Acting Anti-Obesity Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peripherally Acting Anti-Obesity Drug Key Company Manufacturing Base & Headquarters Table 12. Global Peripherally Acting Anti-Obesity Drug Company, Product Type & Application Table 13. Global Peripherally Acting Anti-Obesity Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peripherally Acting Anti-Obesity Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Prescription Drugs Table 18. Significant Companies of Non-prescription Drugs Table 19. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Type (2021-2026) & (k units) Table 21. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Type (2027-2032) & (k units) Table 22. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Type (2021-2026) Table 23. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Type (2027-2032) Table 24. Global Peripherally Acting Anti-Obesity Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peripherally Acting Anti-Obesity Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Peripherally Acting Anti-Obesity Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Type (2021-2026) Table 28. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Online Pharmacies Table 30. Significant Companies of Hospital Pharmacies Table 31. Significant Companies of Retail Pharmacies Table 32. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Application (2021-2026) & (k units) Table 34. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Application (2027-2032) & (k units) Table 35. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Application (2021-2026) Table 36. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Application (2027-2032) Table 37. Global Peripherally Acting Anti-Obesity Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Peripherally Acting Anti-Obesity Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Peripherally Acting Anti-Obesity Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Application (2021-2026) Table 41. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Application (2027-2032) Table 42. Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026) & (k units) Table 44. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2021-2026) Table 45. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2027-2032) & (k units) Table 46. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2027-2032) Table 47. Global Peripherally Acting Anti-Obesity Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Peripherally Acting Anti-Obesity Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Region (2021-2026) Table 50. Global Peripherally Acting Anti-Obesity Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Region (2027-2032) Table 52. Global Peripherally Acting Anti-Obesity Drug Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Peripherally Acting Anti-Obesity Drug Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Peripherally Acting Anti-Obesity Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Peripherally Acting Anti-Obesity Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 57. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2026) Table 58. Global Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 59. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2027-2032) Table 60. Global Peripherally Acting Anti-Obesity Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Peripherally Acting Anti-Obesity Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Peripherally Acting Anti-Obesity Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Peripherally Acting Anti-Obesity Drug Sales Value Market Share by Country (2027-2032) Table 64. Novo Nordisk A/S Company Information Table 65. Novo Nordisk A/S Business Overview Table 66. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio Table 68. Novo Nordisk A/S Recent Development Table 69. Pfizer Inc. Company Information Table 70. Pfizer Inc. Business Overview Table 71. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 73. Pfizer Inc. Recent Development Table 74. GlaxoSmithKline plc Company Information Table 75. GlaxoSmithKline plc Business Overview Table 76. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio Table 78. GlaxoSmithKline plc Recent Development Table 79. Vivus LLC. Company Information Table 80. Vivus LLC. Business Overview Table 81. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 83. Vivus LLC. Recent Development Table 84. Rhythm Pharmaceuticals Company Information Table 85. Rhythm Pharmaceuticals Business Overview Table 86. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio Table 88. Rhythm Pharmaceuticals Recent Development Table 89. KVK Tech Inc. Company Information Table 90. KVK Tech Inc. Business Overview Table 91. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 93. KVK Tech Inc. Recent Development Table 94. Gelesis Holdings Company Information Table 95. Gelesis Holdings Business Overview Table 96. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio Table 98. Gelesis Holdings Recent Development Table 99. Currax Pharmaceuticals LLC Company Information Table 100. Currax Pharmaceuticals LLC Business Overview Table 101. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio Table 103. Currax Pharmaceuticals LLC Recent Development Table 104. CHEPLAPHARM Arzneimittel GmbH Company Information Table 105. CHEPLAPHARM Arzneimittel GmbH Business Overview Table 106. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 108. CHEPLAPHARM Arzneimittel GmbH Recent Development Table 109. Boehringer Ingelheim International GmbH Company Information Table 110. Boehringer Ingelheim International GmbH Business Overview Table 111. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 113. Boehringer Ingelheim International GmbH Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Peripherally Acting Anti-Obesity Drug Distributors List Table 117. Peripherally Acting Anti-Obesity Drug Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Peripherally Acting Anti-Obesity Drug Product Image Figure 2. Global Peripherally Acting Anti-Obesity Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peripherally Acting Anti-Obesity Drug Sales (2021-2032) & (k units) Figure 5. Global Peripherally Acting Anti-Obesity Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Peripherally Acting Anti-Obesity Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Prescription Drugs Image Figure 10. Non-prescription Drugs Image Figure 11. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Peripherally Acting Anti-Obesity Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Peripherally Acting Anti-Obesity Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Type (2021-2032) Figure 17. Online Pharmacies Image Figure 18. Hospital Pharmacies Image Figure 19. Retail Pharmacies Image Figure 20. Global Peripherally Acting Anti-Obesity Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Peripherally Acting Anti-Obesity Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Peripherally Acting Anti-Obesity Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Application (2021-2032) Figure 26. Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Peripherally Acting Anti-Obesity Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Peripherally Acting Anti-Obesity Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Peripherally Acting Anti-Obesity Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Peripherally Acting Anti-Obesity Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Peripherally Acting Anti-Obesity Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Peripherally Acting Anti-Obesity Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • Non-prescription Drugs
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/S
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Vivus LLC.
  • Rhythm Pharmaceuticals
  • KVK Tech Inc.
  • Gelesis Holdings
  • Currax Pharmaceuticals LLC
  • CHEPLAPHARM Arzneimittel GmbH
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032)
  4. 1.2.2 Global Peripherally Acting Anti-Obesity Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Peripherally Acting Anti-Obesity Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peripherally Acting Anti-Obesity Drug Market Dynamics
  1. 2.1 Peripherally Acting Anti-Obesity Drug Industry Trends
  2. 2.2 Peripherally Acting Anti-Obesity Drug Industry Drivers
  3. 2.3 Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges
  4. 2.4 Peripherally Acting Anti-Obesity Drug Industry Restraints
3 Peripherally Acting Anti-Obesity Drug Market by Company
  1. 3.1 Global Peripherally Acting Anti-Obesity Drug Company Revenue Ranking in 2025
  2. 3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Company (2021-2026)
  3. 3.3 Global Peripherally Acting Anti-Obesity Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Peripherally Acting Anti-Obesity Drug Average Price by Company (2021-2026)
  5. 3.5 Global Peripherally Acting Anti-Obesity Drug Company Ranking (2024-2026)
  6. 3.6 Global Peripherally Acting Anti-Obesity Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Peripherally Acting Anti-Obesity Drug Company Product Type and Application
  8. 3.8 Global Peripherally Acting Anti-Obesity Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peripherally Acting Anti-Obesity Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peripherally Acting Anti-Obesity Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peripherally Acting Anti-Obesity Drug Market by Type
  1. 4.1 Peripherally Acting Anti-Obesity Drug Type Introduction
  2. 4.1.1 Prescription Drugs
  3. 4.1.2 Non-prescription Drugs
  4. 4.2 Global Peripherally Acting Anti-Obesity Drug Sales Volume by Type
  5. 4.2.1 Global Peripherally Acting Anti-Obesity Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peripherally Acting Anti-Obesity Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Peripherally Acting Anti-Obesity Drug Sales Value by Type
  9. 4.3.1 Global Peripherally Acting Anti-Obesity Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peripherally Acting Anti-Obesity Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Type (2021-2032)
5 Peripherally Acting Anti-Obesity Drug Market by Application
  1. 5.1 Peripherally Acting Anti-Obesity Drug Application Introduction
  2. 5.1.1 Online Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Peripherally Acting Anti-Obesity Drug Sales Volume by Application
  6. 5.2.1 Global Peripherally Acting Anti-Obesity Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peripherally Acting Anti-Obesity Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Peripherally Acting Anti-Obesity Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Peripherally Acting Anti-Obesity Drug Sales Value by Application
  10. 5.3.1 Global Peripherally Acting Anti-Obesity Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peripherally Acting Anti-Obesity Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Peripherally Acting Anti-Obesity Drug Sales Value Share by Application (2021-2032)
6 Peripherally Acting Anti-Obesity Drug Regional Sales and Value Analysis
  1. 6.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Peripherally Acting Anti-Obesity Drug Sales by Region (2027-2032)
  5. 6.3 Global Peripherally Acting Anti-Obesity Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peripherally Acting Anti-Obesity Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peripherally Acting Anti-Obesity Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peripherally Acting Anti-Obesity Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Peripherally Acting Anti-Obesity Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032)
  12. 6.6.2 North America Peripherally Acting Anti-Obesity Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Peripherally Acting Anti-Obesity Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032)
  21. 6.9.2 South America Peripherally Acting Anti-Obesity Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Value Share by Country, 2025 VS 2032
7 Peripherally Acting Anti-Obesity Drug Country-level Sales and Value Analysis
  1. 7.1 Global Peripherally Acting Anti-Obesity Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peripherally Acting Anti-Obesity Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032)
  6. 7.4 Global Peripherally Acting Anti-Obesity Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peripherally Acting Anti-Obesity Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peripherally Acting Anti-Obesity Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peripherally Acting Anti-Obesity Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peripherally Acting Anti-Obesity Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peripherally Acting Anti-Obesity Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk A/S
  2. 8.1.1 Novo Nordisk A/S Company Information
  3. 8.1.2 Novo Nordisk A/S Business Overview
  4. 8.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio
  6. 8.1.5 Novo Nordisk A/S Recent Developments
  7. 8.2 Pfizer Inc.
  8. 8.2.1 Pfizer Inc. Company Information
  9. 8.2.2 Pfizer Inc. Business Overview
  10. 8.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  12. 8.2.5 Pfizer Inc. Recent Developments
  13. 8.3 GlaxoSmithKline plc
  14. 8.3.1 GlaxoSmithKline plc Company Information
  15. 8.3.2 GlaxoSmithKline plc Business Overview
  16. 8.3.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio
  18. 8.3.5 GlaxoSmithKline plc Recent Developments
  19. 8.4 Vivus LLC.
  20. 8.4.1 Vivus LLC. Company Information
  21. 8.4.2 Vivus LLC. Business Overview
  22. 8.4.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio
  24. 8.4.5 Vivus LLC. Recent Developments
  25. 8.5 Rhythm Pharmaceuticals
  26. 8.5.1 Rhythm Pharmaceuticals Company Information
  27. 8.5.2 Rhythm Pharmaceuticals Business Overview
  28. 8.5.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio
  30. 8.5.5 Rhythm Pharmaceuticals Recent Developments
  31. 8.6 KVK Tech Inc.
  32. 8.6.1 KVK Tech Inc. Company Information
  33. 8.6.2 KVK Tech Inc. Business Overview
  34. 8.6.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  36. 8.6.5 KVK Tech Inc. Recent Developments
  37. 8.7 Gelesis Holdings
  38. 8.7.1 Gelesis Holdings Company Information
  39. 8.7.2 Gelesis Holdings Business Overview
  40. 8.7.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio
  42. 8.7.5 Gelesis Holdings Recent Developments
  43. 8.8 Currax Pharmaceuticals LLC
  44. 8.8.1 Currax Pharmaceuticals LLC Company Information
  45. 8.8.2 Currax Pharmaceuticals LLC Business Overview
  46. 8.8.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio
  48. 8.8.5 Currax Pharmaceuticals LLC Recent Developments
  49. 8.9 CHEPLAPHARM Arzneimittel GmbH
  50. 8.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information
  51. 8.9.2 CHEPLAPHARM Arzneimittel GmbH Business Overview
  52. 8.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  54. 8.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments
  55. 8.10 Boehringer Ingelheim International GmbH
  56. 8.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 8.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 8.10.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  60. 8.10.5 Boehringer Ingelheim International GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peripherally Acting Anti-Obesity Drug Value Chain Analysis
  2. 9.1.1 Peripherally Acting Anti-Obesity Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peripherally Acting Anti-Obesity Drug Sales Mode & Process
  6. 9.2 Peripherally Acting Anti-Obesity Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peripherally Acting Anti-Obesity Drug Distributors
  9. 9.2.3 Peripherally Acting Anti-Obesity Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst